Beacon Investment Advisory Services Inc. Sells 16,762 Shares of DexCom, Inc. (NASDAQ:DXCM)

Beacon Investment Advisory Services Inc. trimmed its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 2.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 688,866 shares of the medical device company's stock after selling 16,762 shares during the period. DexCom comprises 1.9% of Beacon Investment Advisory Services Inc.'s holdings, making the stock its 10th biggest holding. Beacon Investment Advisory Services Inc. owned about 0.18% of DexCom worth $46,182,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also added to or reduced their stakes in the company. B. Riley Wealth Advisors Inc. lifted its holdings in DexCom by 132.0% during the first quarter. B. Riley Wealth Advisors Inc. now owns 3,766 shares of the medical device company's stock worth $522,000 after buying an additional 2,143 shares during the period. Cetera Investment Advisers boosted its position in DexCom by 76.4% during the first quarter. Cetera Investment Advisers now owns 106,881 shares of the medical device company's stock valued at $14,824,000 after purchasing an additional 46,297 shares in the last quarter. GAMMA Investing LLC grew its stake in DexCom by 8.1% in the second quarter. GAMMA Investing LLC now owns 3,300 shares of the medical device company's stock valued at $374,000 after purchasing an additional 248 shares during the last quarter. Massmutual Trust Co. FSB ADV raised its holdings in DexCom by 23.8% in the second quarter. Massmutual Trust Co. FSB ADV now owns 1,150 shares of the medical device company's stock worth $130,000 after purchasing an additional 221 shares in the last quarter. Finally, Mather Group LLC. lifted its position in shares of DexCom by 42.7% during the second quarter. Mather Group LLC. now owns 1,263 shares of the medical device company's stock valued at $143,000 after buying an additional 378 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Insider Activity

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the company's stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. This represents a 0.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Sadie Stern sold 4,259 shares of the firm's stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the sale, the executive vice president now owns 71,192 shares in the company, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 5,431 shares of company stock valued at $399,319 in the last quarter. 0.30% of the stock is currently owned by company insiders.

DexCom Stock Performance

NASDAQ:DXCM traded up $1.32 during mid-day trading on Monday, hitting $79.31. The company's stock had a trading volume of 3,277,582 shares, compared to its average volume of 3,921,273. The business's fifty day moving average is $71.39 and its two-hundred day moving average is $87.55. The stock has a market cap of $30.98 billion, a price-to-earnings ratio of 47.49, a PEG ratio of 2.38 and a beta of 1.17. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Sanford C. Bernstein lifted their price objective on shares of DexCom from $82.00 to $86.00 and gave the stock an "outperform" rating in a research report on Friday, October 25th. JPMorgan Chase & Co. upped their price target on DexCom from $75.00 to $85.00 and gave the stock a "neutral" rating in a research report on Friday, October 25th. Raymond James decreased their price objective on DexCom from $115.00 to $99.00 and set a "strong-buy" rating for the company in a report on Friday, October 25th. Stifel Nicolaus upped their target price on DexCom from $90.00 to $100.00 and gave the company a "buy" rating in a research report on Friday, August 23rd. Finally, Piper Sandler reiterated an "overweight" rating and issued a $90.00 price target on shares of DexCom in a research note on Monday, August 26th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $104.59.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.